Eren Demirhan

1.4k total citations · 1 hit paper
15 papers, 955 citations indexed

About

Eren Demirhan is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Eren Demirhan has authored 15 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Hematology and 6 papers in Oncology. Recurrent topics in Eren Demirhan's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Prostate Cancer Treatment and Research (5 papers). Eren Demirhan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Prostate Cancer Treatment and Research (5 papers). Eren Demirhan collaborates with scholars based in United States, Switzerland and Italy. Eren Demirhan's co-authors include Katharina Modelska, Per Rathenborg, De Phung, Andrew Krivoshik, Maha Hussain, Fred Saad, Karim Fizazi, Neal D. Shore, Cora N. Sternberg and Ubirajara Ferreira and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Eren Demirhan

14 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

2018 677 citations Maha Hussain, Karim Fizazi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eren Demirhan United States	8	678	290	231	219	201	15	955
Andrea Zivi United Kingdom	15	643 0.9×	185 0.6×	283 1.2×	284 1.3×	346 1.7×	46	950
Julie S. Larsen United States	13	1.3k 1.9×	322 1.1×	416 1.8×	494 2.3×	303 1.5×	31	1.8k
Deborah Ricci United States	15	399 0.6×	474 1.6×	262 1.1×	68 0.3×	261 1.3×	51	876
Georg Stüben Germany	20	624 0.9×	488 1.7×	147 0.6×	155 0.7×	193 1.0×	46	1.2k
S. Chowdhury United Kingdom	16	699 1.0×	267 0.9×	291 1.3×	242 1.1×	290 1.4×	58	951
Karen J. Ferrante United States	9	741 1.1×	862 3.0×	133 0.6×	100 0.5×	354 1.8×	18	1.2k
Huamao Mark Lin United States	18	618 0.9×	582 2.0×	166 0.7×	42 0.2×	317 1.6×	73	1.0k
Mustapha Chadjaa France	11	542 0.8×	283 1.0×	240 1.0×	232 1.1×	136 0.7×	34	756
Adrian Langleben Canada	17	416 0.6×	725 2.5×	158 0.7×	72 0.3×	316 1.6×	55	1.1k
Julia Shelkey United States	6	821 1.2×	190 0.7×	303 1.3×	246 1.1×	239 1.2×	9	956

Countries citing papers authored by Eren Demirhan

Since Specialization

Citations

This map shows the geographic impact of Eren Demirhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eren Demirhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eren Demirhan more than expected).

Fields of papers citing papers by Eren Demirhan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eren Demirhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eren Demirhan. The network helps show where Eren Demirhan may publish in the future.

Co-authorship network of co-authors of Eren Demirhan

This figure shows the co-authorship network connecting the top 25 collaborators of Eren Demirhan. A scholar is included among the top collaborators of Eren Demirhan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eren Demirhan. Eren Demirhan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Tees, Michael, Sattva S. Neelapu, Parameswaran Hari, et al.. (2021). Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.. Journal of Clinical Oncology. 39(15_suppl). 2527–2527. 12 indexed citations

Locke, Frederick L., Shahbaz A. Malik, Michael Tees, et al.. (2021). First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.. Journal of Clinical Oncology. 39(15_suppl). 2529–2529. 21 indexed citations

Neelapu, Sattva S., Javier Muñoz, Frederick L. Locke, et al.. (2020). First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.. Journal of Clinical Oncology. 38(15_suppl). 8002–8002. 38 indexed citations

Saad, Fred, David F. Penson, Gerhardt Attard, et al.. (2018). MP52-19 IMPACT OF ENZALUTAMIDE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PROSPER STUDY RESULTS. The Journal of Urology. 199(4S). 3 indexed citations

Hussain, Maha, Karim Fizazi, Fred Saad, et al.. (2018). Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 378(26). 2465–2474. 677 indexed citations breakdown →

Sternberg, Cora N., Karim Fizazi, Fred Saad, et al.. (2018). Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER. European Urology Supplements. 17(2). e868–e869.

Shore, Neal D., Fred Saad, Maha Hussain, et al.. (2018). PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE. The Journal of Urology. 199(4S). 1 indexed citations

Hussain, Maha, Karim Fizazi, Fred Saad, et al.. (2018). PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).. Journal of Clinical Oncology. 36(6_suppl). 3–3. 26 indexed citations

Larson, Richard A., Ophelia Yin, Andreas Hochhaus, et al.. (2011). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology. 68(5). 723–733. 82 indexed citations

10.

Yin, Ophelia, Neil J. Gallagher, Eren Demirhan, et al.. (2010). Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib. The Journal of Clinical Pharmacology. 50(8). 960–967. 67 indexed citations

11.

Kim, Dongwook, Yu Jin, Sa-Hee Park, et al.. (2010). Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. British Journal of Clinical Pharmacology. 71(2). 199–206. 17 indexed citations

12.

Hughes, Timothy P., Phillipp D. Le Coutre, Richard E. Clark, et al.. (2010). Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.. Journal of Clinical Oncology. 28(15_suppl). 6556–6556. 1 indexed citations

13.

Kim, Dong‐Wook, Camille Granvil, Eren Demirhan, et al.. (2009). Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibi. Blood. 114(22). 1–1. 3 indexed citations

14.

Gallagher, Neil J., Eren Demirhan, Wei Zhou, et al.. (2009). Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. Journal of Clinical Oncology. 27(15_suppl). 7053–7053. 4 indexed citations

15.

Kim, Dong-Wook, Camille Granvil, Eren Demirhan, et al.. (2009). Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.. Blood. 114(22). 1127–1127. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact